Ad26.COV2.S

AXP000168.2 · Vaccine

Platform
human adenovirus 26 (non-replicating)
Targets
SARS-CoV-2 S
Originator
Janssen Vaccines & Prevention (Crucell)
Sponsor
Johnson & Johnson

Names

NameTypeSource
Ad26.COV2.Spreferred name, codecurator, wikidata
Jcovdenbrandwikidata
Ad26COVS1codewikidata
JNJ-78436735codewikidata
VAC31518codewikidata
COVID-19 Vaccine Janssenformer namewikidata

Virus

Role
Vaccine vector
Family
Adenoviridae
Virus
human adenovirus 26
Strain
Ad26
Replication
non replicating
Modifications
E1-deleted, replication-incompetent Ad26; stabilised SARS-CoV-2 spike transgene; produced in PER.C6 cells
Transgenes
SARS-CoV-2 spike
Route
intramuscular
Source
evidence

Cross-references

Wikidata
Q98655215
FDA UNII
JT2NS6183B

Approvals

AgencyRegionDateStatusBrandIndicationSource
FDAUS2021-02-27conditionalJanssen COVID-19 VaccinePrevention of COVID-19 in individuals 18 years and older (emergency use authorisation)source
EMAEU2021-03-11conditionalJcovdenActive immunisation to prevent COVID-19 in people aged 18 years and oldersource
EMAEU2023-01-09approvedJcovdenStandard marketing authorisation, converted from conditionalsource
FDAUS2023-06withdrawnJanssen COVID-19 VaccineEmergency use authorisation revoked at the manufacturer's requestsource
EMAEU2024-07-26withdrawnJcovdenAuthorisation withdrawn at the holder's request for commercial reasonssource

Clinical trials (33)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05571735Immunogenicity of COVID-19 Vaccines in Tuberculosis PatientsRecruiting2023-04-152026-06-30133Covid-19 Pandemics; Tuberculosis
NCT05515042Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults.UnknownPhase 22022-07-252024-06-30694COVID-19
NCT05697705Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil StudyCompleted2022-07-222023-05-18188814085COVID-19
NCT05844202Safety, Tolerability and Immunogenicity of Alveavax-v1.2, a BA.2/Omicron-optimized, DNA Vaccine for COVID-19 PreventionCompletedPhase 12022-06-272023-03-02130Sars-CoV-2 Infection
NCT05409261Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 VaccineUnknownPhase 22022-06-022022-09-25200COVID-19; SARS CoV 2 Infection; Vaccine Adverse Reaction; Vaccine Reaction
NCT05220397Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant RecipientsTerminatedPhase 32022-04-112025-02-28468Kidney Transplant Recipient
NCT04998240Mix and Match Heterologous Prime-Boost Study Using Approved COVID-19 VaccinesUnknownPhase 22021-12-292022-09-26360Covid19
NCT05109559Ad26.COV2.S as a Heterologous Booster in Adults After Single- or Two-Dose of Inactivated COVID-19 VaccineUnknownPhase 1/22021-12-202023-12690SARS-CoV-2 Infection
NCT05178264Transverse Myelitis Related to SARS-CoV-2 VaccinesCompleted2021-12-102021-12-10580Vaccine Adverse Reaction
NCT05148845Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study.CompletedPhase 32021-11-102022-01-31500000SARS CoV 2 Infection
NCT05052307A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in BrazilCompleted2021-11-032022-06-204574Covid19
NCT05091307A Study of Ad26.COV2.S and Influenza Vaccines in Healthy AdultsCompletedPhase 32021-11-022022-06-17861COVID-19 Prevention
NCT05030974RECOVAC Repeated Vaccination StudyCompletedPhase 42021-10-212022-03-12336Covid19; Kidney Diseases; SARS-CoV2 Infection; Vaccine Response Impaired
NCT05007080A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years InclusiveCompletedPhase 22021-09-272023-08-14304Coronavirus Disease-2019 (COVID-19) Prevention
NCT05037266Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older - 55 to 65 Years. Covicompare-JanssenTerminatedPhase 42021-09-202022-02-1427Healthy Volunteers
NCT04765384A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)CompletedPhase 22021-08-272023-11-2451COVID-19 Prevention
NCT05000216COVID-19 Booster Vaccine in Autoimmune Disease Non-RespondersTerminatedPhase 22021-08-132023-06-22258Juvenile Dermatomyositis (JDM); Juvenile Idiopathic Arthritis (JIA); Multiple Sclerosis (MS); Pediatric SLE; Pediatric-Onset Multiple Sclerosis (POMS); Pemphigus Vulgaris; Rheumatoid Arthritis (RA); Systemic Lupus Erythematosus (SLE); Systemic Sclerosis (SSc)
NCT04999111A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2CompletedPhase 22021-08-062021-10-271541Coronavirus Disease
NCT04930055Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)Terminated2021-06-302021-11-012206Cancer
NCT04908722A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy AdultsCompletedPhase 32021-06-182023-07-101609COVID-19 Prevention
NCT05324319Homologous vs Heterologous Third Vaccination in Kidney Transplant Recipients Kidney Transplant RecipientsUnknownPhase 22021-06-152022-07-31200COVID-19
NCT04889209Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA VaccinesCompletedPhase 1/22021-05-282023-06-16867COVID-19
NCT04894305A Study of Ad26.COV2.S in Healthy Adults (COVID-19)CompletedPhase 12021-05-252021-12-08380Healthy
NCT04834869COVID-19 Vaccines Safety Tracking (CoVaST)Recruiting2021-04-012025-12-3130000Adverse Reaction to Vaccine; COVID19 Vaccine
NCT04838795Sisonke (Together): OPEN LABEL TRIAL COVID-19CompletedPhase 32021-02-172022-03-31477102SARS (Severe Acute Respiratory Syndrome)
NCT04832932The COVID-19 Back-to-Normal Study: Analysis of Multiple OutcomesUnknown2021-01-052023-01-052000COVID-19 Vaccines
NCT04614948A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in AdultsCompletedPhase 32020-11-122023-06-1831835Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19
NCT04505722A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult ParticipantsCompletedPhase 32020-09-072023-03-3144325Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol
NCT04535453A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults and AdolescentsCompletedPhase 22020-08-282022-03-09635Healthy
NCT04509947A Study of Ad26.COV2.S in Adults (COVID-19)CompletedPhase 12020-08-112021-02-22250Healthy
NCT05007860Vaccine Responsiveness in Patients With Chronic Lymphocytic LeukemiaCompleted2020-07-162021-06-3036Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT04436276A Study of Ad26.COV2.S in Adults (COVID-19)CompletedPhase 1/22020-07-152023-02-211085Covid-19 Prevention
NCT04817657Pre-approval Access for Janssen's COVID Vaccine VAC31518 for Treating Physician UseNo longer availableHealthy
Unconfirmed matches (2)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT07408297Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and RwandaCompletedPhase 22022-05-182024-06-271919COVID -19; SARS CoV 2 Infectionname in intervention: Ad26COVS1
NCT05047640COVID-19 3rd Dose Vaccine in Transplant PatientsTerminatedPhase 32021-09-142022-10-2558Covid19name in intervention: JNJ-78436735

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41690324Safety and immunogenicity of a single dose of Ad26.COV2.S, BNT162b2, or SARS-CoV-2-rS-protein-nanoparticle in previously vaccinated and unvaccinated adults living with and without HIV in South Africa: a phase 2a randomised, observer-blind trial.The lancet. HIV2026cited by trial NCT05515042
PMID 42061096A randomized, observer-blind, phase 1 study of immune responses to three human adenovirus type 26 vector-based vaccines.EBioMedicine2026name in abstract: Ad26.COV2.S
PMID 42085933Early transcriptional responses following Ad26.COV2.S vaccination in individuals with prior SARS-CoV-2 infection.EBioMedicine2026name in title: Ad26.COV2.S
PMID 42951458Association Between Acute Vulvar Ulcers and Gene-Based COVID-19 Vaccines.Taiwanese journal of obstetrics & gynecology2026name in abstract: Ad26.COV2.S
PMID 39817585Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.Journal of medical virology2025name in abstract: Ad26.COV2.S
PMID 39866854Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trial.EClinicalMedicine2025cited by trial NCT05091307
PMID 39868766Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial.Human vaccines & immunotherapeutics2025cited by trial NCT05007080
PMID 40014936Vaccine effectiveness of JCOVDEN single-dose against COVID-19 hospitalisation in Europe: An id.DRIVE test-negative case-control study.Journal of infection and public health2025name in title: Jcovden
PMID 40068393Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron.Vaccine2025cited by trial NCT05697705
PMID 40298376Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.The Journal of infectious diseases2025cited by trial NCT04889209
PMID 40425703Serious adverse drug reactions associated with anti-SARS-CoV-2 vaccines and their reporting trends in the EudraVigilance database.Scientific reports2025name in abstract: Jcovden
PMID 40663029Responses of Kidney Transplant Recipients to Vaccination and Boosting.Mayo Clinic proceedings2025cited by trial NCT05220397
PMID 40694514Immunogenicity and Safety of Heterologous Versus Homologous Prime-Boost Regimens With BBIBP-CorV and Ad26.COV2.S COVID-19 Vaccines: A Multicentric, Randomized, Observer-Blinded Non-inferiority Trial in Madagascar and Mozambique.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America2025cited by trial NCT04998240
PMID 40730836Safety and immunogenicity of fractional COVID-19 vaccine doses in Nigerian adults: A randomized non-inferiority trial.Scientific reports2025name in abstract: Ad26.COV2.S
PMID 40808283Safety, immunogenicity and pregnancy outcomes in mothers and infants after vaccination with an adenovirus-vector COVID-19 vaccine during pregnancy.Human vaccines & immunotherapeutics2025cited by trial NCT04765384
PMID 41239286Long-term trends in reporting of cardiac adverse drug reactions to COVID-19 vaccines - an exploratory analysis of the EudraVigilance database.BMC infectious diseases2025name in abstract: Jcovden
PMID 41289027Prospective SARS-CoV-2 additional vaccination in immunosuppressant-treated individuals with autoimmune diseases in a randomized controlled trial.JCI insight2025cited by trial NCT05000216
PMID 41378554Clot twist - D-dimer analysis of healthy adults receiving heterologous or homologous booster COVID-19 vaccine after a single prime dose of Ad26.COV2.S in a phase II randomised open-label trial, BaSiS.South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde2025name in title: Ad26.COV2.S
PMID 41402886A triple-blinded randomized control trial to evaluate the safety and immunogenicity of fractional doses of COVID-19 vaccines (ChAd0x1, AD26.COV2. S, and BNT162B2) among Nigeria adults: the SIFCoVAN trial.Trials2025name in title: Ad26.COV2.S
PMID 37992183The Novavax Heterologous Coronavirus Disease 2019 Booster Demonstrates Lower Reactogenicity Than Messenger RNA: A Targeted Review.The Journal of infectious diseases2024cited by trial NCT04889209
PMID 38278629Safety of a second homologous Ad26.COV2.S vaccine among healthcare workers in the phase 3b implementation Sisonke study in South Africa.Vaccine2024cited by trial NCT05148845
PMID 38467646Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features.Nature communications2024cited by trial NCT04505722
PMID 38705804Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study.Vaccine2024cited by trial NCT04535453
PMID 38744598Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial.Vaccine2024cited by trial NCT05109559
PMID 38762522Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters.Nature communications2024name in abstract: Ad26.COV2.S
PMID 38902860Repeated COVID-19 Vaccination Drives Memory T- and B-cell Responses in Kidney Transplant Recipients: Results From a Multicenter Randomized Controlled Trial.Transplantation2024cited by trial NCT05030974
PMID 38918103Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial.Vaccine2024cited by trial NCT04999111
PMID 38958922Acquired immune thrombotic thrombocytopenic purpura (TTP) associated with inactivated COVID-19 vaccine CoronaVac.Frontiers of medicine2024name in abstract: Ad26.COV2.S
PMID 39111095Optic neuritis following COVID-19 vaccination: Case series and review of the literature.Journal francais d'ophtalmologie2024name in abstract: Ad26.COV2.S
PMID 39121698Pre- and post-Ad26.COV2·S booster dose antibody levels predict COVID-19 disease risk.Vaccine2024cited by trial NCT04999111
PMID 39225478Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials.The Journal of infectious diseases2024cited by trial NCT04505722
PMID 39272117Patient engagement as a collaborative process in a large Dutch COVID-19 vaccination study (RECOVAC) - insight into the contribution of patient engagement and learnings for the future.Research involvement and engagement2024cited by trial NCT05030974
PMID 39470514Polymyalgia rheumatica following COVID-19 vaccination: Case series of 3 patients and literature review on polymyalgia rheumatica induced by various vaccines.Medicine2024name in abstract: Ad26.COV2.S
PMID 39532861Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial.Nature communications2024cited by trial NCT04505722
PMID 39697294An observational post-authorization study to assess the effectiveness of a single dose Ad26.COV2.S for the prevention of COVID-19 using real-world data.Frontiers in public health2024name in title: Ad26.COV2.S
PMID 35605819Serological response to vaccines against SARS-CoV-2 in patients with inflammatory bowel disease.Gastroenterologia y hepatologia2023name in abstract: Ad26.COV2.S
PMID 36057889Case reports of management of aplastic anemia after COVID-19 vaccination: a single institute experience in Taiwan.International journal of hematology2023name in abstract: Ad26.COV2.S
PMID 36211224Systemic lupus erythematosus myocarditis after COVID-19 vaccination.Reumatologia clinica2023name in abstract: Ad26.COV2.S
PMID 36354032Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial.The Lancet. Infectious diseases2023cited by trial NCT05030974
PMID 36398559Guillain-Barré syndrome after COVID-19 vaccines: A Tunisian case series.British journal of clinical pharmacology2023name in abstract: Ad26.COV2.S
PMID 36458888An observational study of adverse drug reactions to COVID-19 vaccines reported to the New Mexico poison center hotline.Clinical toxicology (Philadelphia, Pa.)2023name in abstract: Ad26.COV2.S
PMID 36466142Localized eczematous rash affecting left and right regions of breast and shoulder after Ad26.COV2.S vaccine against COVID-19 in a 30-year-old woman with comorbidities.Allergo journal international2023name in title: Ad26.COV2.S
PMID 36539057The type of SARS-CoV-2 vaccine does not affect ovarian function in assisted reproduction cycle.Fertility and sterility2023name in abstract: Ad26.COV2.S
PMID 36643729Acute disseminated encephalomyelitis following the COVID-19 vaccine Ad26.COV2.S, a case report.Bulletin of the National Research Centre2023name in title: Ad26.COV2.S
PMID 36694608Cerebral venous sinus thrombosis after COVID-19 vaccination: a case report and literature review.Oxford medical case reports2023name in abstract: Ad26.COV2.S
PMID 36732164Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan.Vaccine2023cited by trial NCT04509947
PMID 36739118Systemic lupus erythematosus myocarditis after COVID-19 vaccination.Reumatologia clinica2023name in abstract: Ad26.COV2.S
PMID 36741657A Case of Vaccine-Induced Thrombocytopenic Thrombosis Manifesting as Cerebral Venous Thrombosis and Intracerebral Bleed.Cureus2023name in abstract: Ad26.COV2.S
PMID 36817454Case Report: mRNA vaccination-mediated STAT3 overactivation with agranulocytosis and clonal T-LGL expansion.Frontiers in immunology2023name in abstract: Ad26.COV2.S
PMID 36828523Concomitant Severe Psoriasis and Bullous Pemphigoid Induced by COVID-19.Tropical medicine and infectious disease2023name in abstract: Ad26.COV2.S
PMID 36852853Two Case Reports of Chronic Inflammatory Demyelinating Polyneuropathy After COVID-19 Vaccination.Journal of Korean medical science2023name in abstract: Ad26.COV2.S
PMID 36928720COVID-19 vaccine-associated myositis: a comprehensive review of the literature driven by a case report.Immunologic research2023name in abstract: Ad26.COV2.S
PMID 36975207Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial.eLife2023name in abstract: Ad26.COV2.S
PMID 37038643COVID-19 Vaccine-Associated Pneumonitis in the Republic of Korea: A Nationwide Multicenter Survey.Journal of Korean medical science2023name in abstract: Ad26.COV2.S
PMID 37063238Vascular thrombosis after single dose Ad26.COV2.S vaccine in healthcare workers in South Africa: open label, single arm, phase 3B study (Sisonke study).BMJ medicine2023cited by trial NCT04838795
PMID 37085049Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.The Journal of infection2023name in abstract: Ad26.COV2.S
PMID 37087559Kidney Transplantation from a Deceased Donor with COVID-19 Ad26.COV2-S Vaccine-Induced Thrombotic Thrombocytopenia.The American journal of case reports2023name in title: Ad26.COV2.S
PMID 37088096Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.The Lancet. Infectious diseases2023name in abstract: Ad26.COV2.S
PMID 37091963A Pilot Single-Blinded, Randomized, Controlled Trial Comparing BNT162b2 vs. JNJ-78436735 Vaccine as the Third Dose After Two Doses of BNT162b2 Vaccine in Solid Organ Transplant Recipients.Transplant international : official journal of the European Society for Organ Transplantation2023name in title: JNJ-78436735
PMID 37195456Psychometric evaluation of the Symptoms of Infection with Coronavirus-19 (SIC): results from a cross-sectional study and a phase 3 clinical trial.Journal of patient-reported outcomes2023name in abstract: Ad26.COV2.S
PMID 37344265Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.Vaccine2023cited by trial NCT05109559
PMID 37385888Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials.Vaccine2023cited by trial NCT04505722
PMID 37433788Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants.NPJ vaccines2023cited by trial NCT04889209
PMID 37652823Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults.Vaccine2023name in abstract: Ad26.COV2.S
PMID 34254358Participation in ENSEMBLE phase III multicenter clinical trial of Ad26.CoV2.S, a COVID-19 vaccine: An investigational drug services perspective.Journal of clinical pharmacy and therapeutics2022name in title: Ad26.COV2.S
PMID 34269723DOTATATE Uptake in an Axillary Lymph Node After COVID-19 Vaccination.Clinical nuclear medicine2022name in abstract: COVID-19 Vaccine Janssen
PMID 34420869Temporal Association Between the COVID-19 Ad26.COV2.S Vaccine and Acute Myocarditis: A Case Report and Literature Review.Cardiovascular revascularization medicine : including molecular interventions2022name in title: Ad26.COV2.S
PMID 34614491Successful Treatment of Vaccine-Induced Immune Thrombotic Thrombocytopenia in a 26-Year-Old Female Patient.Acta haematologica2022name in abstract: Ad26.COV2.S
PMID 34626338Fatal vaccine-induced immune thrombotic thrombocytopenia (VITT) post Ad26.COV2.S: first documented case outside US.Infection2022name in title: Ad26.COV2.S
PMID 34672380Refractory vaccine-induced immune thrombotic thrombocytopenia (VITT) managed with delayed therapeutic plasma exchange (TPE).Journal of clinical apheresis2022name in abstract: Ad26.COV2.S
PMID 34872162Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID-19 vaccine in haemato-oncological patients with no antibody response.British journal of haematology2022name in title: Ad26.COV2.S
PMID 34900001Optic neuritis after COVID-19 vaccine application.Clinical & experimental neuroimmunology2022name in abstract: Ad26.COV2.S
PMID 34928302Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial.JAMA internal medicine2022name in abstract: Ad26COVS1
PMID 34986404Vaccine-induced massive pulmonary embolism and thrombocytopenia following a single dose of Janssen Ad26.COV2.S vaccination.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2022name in title: Ad26.COV2.S
PMID 35045226Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.The New England journal of medicine2022name in title: Ad26.COV2.S
PMID 35049005Acute embolisms in multiple arterial districts following Ad26.COV2-S vaccine.European review for medical and pharmacological sciences2022name in title: Ad26.COV2.S
PMID 35071987Sub-acute Onset of Guillain-Barré Syndrome Post-mRNA-1273 Vaccination: a Case Report.SN comprehensive clinical medicine2022name in abstract: Ad26.COV2.S
PMID 35073571Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study.Blood advances2022cited by trial NCT05007860
PMID 35074136Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.Lancet (London, England)2022name in abstract: Ad26.COV2.S
PMID 35081293Homologous and Heterologous Covid-19 Booster Vaccinations.The New England journal of medicine2022cited by trial NCT04889209
PMID 35096528Multisystem Inflammatory Syndrome after Ad26.COV2.S vaccination.IDCases2022name in title: Ad26.COV2.S
PMID 35113987Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient.Blood2022name in abstract: Ad26.COV2.S
PMID 35135671A case report of vaccine-induced immune thrombocytopenia and thrombosis syndrome after Ad26.COV2.S vaccine (Janssen/Johnson & Johnson).Therapie2022name in title: Ad26.COV2.S
PMID 35139271Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S.The New England journal of medicine2022cited by trial NCT04505722
PMID 35144972Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.Clinical journal of the American Society of Nephrology : CJASN2022name in abstract: Ad26.COV2.S
PMID 35157644Guillain-Barré Syndrome After Ad26.COV2.S Vaccination.The American journal of case reports2022name in title: Ad26.COV2.S
PMID 35189775A case of myocarditis following ChAdOx1 nCov-19 vaccination.Acta cardiologica2022name in abstract: Ad26COVS1
PMID 35215900Immunogenicity Following Administration of BNT162b2 and Ad26.COV2.S COVID-19 Vaccines in the Pregnant Population during the Third Trimester.Viruses2022name in title: Ad26.COV2.S
PMID 35217969Cerebral venous thrombosis without thrombocytopenia after a single dose of COVID-19 (Ad26.COV2.S) vaccine injection: a case report.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2022name in title: Ad26.COV2.S
PMID 35276381Adverse events following COVID-19 vaccination in South Korea between February 28 and August 21, 2021: A nationwide observational study.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2022name in abstract: JNJ-78436735
PMID 35277439Stroke Among SARS-CoV-2 Vaccine Recipients in Mexico: A Nationwide Descriptive Study.Neurology2022name in abstract: Ad26.COV2.S
PMID 35305740Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study.Lancet (London, England)2022cited by trial NCT04838795
PMID 35331228Oral erythema multiforme after Pfizer-BioNTech COVID-19 vaccination: a report of four cases.BMC oral health2022name in abstract: Ad26.COV2.S
PMID 35371813Facial Diplegia Variant of Guillain-Barré Syndrome in Pregnancy Following COVID-19 Vaccination: A Case Report.Cureus2022name in abstract: Ad26.COV2.S
PMID 35405168Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.The Journal of infection2022name in abstract: Ad26.COV2.S
PMID 35419151Cerebral Venous Sinus Thrombosis due to Thrombosis with Thrombocytopenia Syndrome Following Ad26.COV2.S: A First Real-World Case Report of a Male Subject.The Neurohospitalist2022name in title: Ad26.COV2.S
PMID 35429381Impact of Preexisting Anti-Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine.The Journal of infectious diseases2022name in title: Ad26.COV2.S
PMID 35444866Not All That Is Droopy Post Ad26.COV2.S (JNJ) Vaccine Is Bell's Palsy: A Rare Case of Isolated Dorsal Pontine Stroke Causing Ipsilateral Complete Hemi-Facial Palsy.Cureus2022name in title: Ad26.COV2.S
PMID 35446353Evaluation of the Durability of the Immune Humoral Response to COVID-19 Vaccines in Patients With Cancer Undergoing Treatment or Who Received a Stem Cell Transplant.JAMA oncology2022name in abstract: JNJ-78436735
PMID 35449682Vaccine-Induced Thrombotic Thrombocytopenia: A Case Report.Cureus2022name in abstract: Ad26.COV2.S
PMID 35494984Vaccine-Induced Thrombotic Thrombocytopenia: A Case of Splanchnic Veins Thrombosis.Cureus2022name in abstract: Ad26.COV2.S
PMID 35512656Ischemic Stroke and Vaccine-Induced Immune Thrombotic Thrombocytopenia following COVID-19 Vaccine: A Case Report with Systematic Review of the Literature.Cerebrovascular diseases (Basel, Switzerland)2022name in abstract: Ad26.COV2.S
PMID 35528839Acute Fulminant Myocarditis After ChAdOx1 nCoV-19 Vaccine: A Case Report and Literature Review.Frontiers in cardiovascular medicine2022name in abstract: Ad26.COV2.S
PMID 35535430Vaccine-induced immune thrombotic thrombocytopenia in a male after Ad26.COV2.S vaccination presenting as cerebral venous sinus thrombosis.Platelets2022name in title: Ad26.COV2.S
PMID 35589271Vaccine-induced immune thrombocytopaenia and thrombosis (VITT) after COVID-19 vaccination.BMJ case reports2022name in abstract: Ad26.COV2.S
PMID 35599706Vaccine-induced prothrombotic immune thrombocytopenia without thrombosis may not require immune modulatory therapy: A case report.Research and practice in thrombosis and haemostasis2022name in abstract: Ad26.COV2.S
PMID 35620997Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2022name in abstract: COVID-19 Vaccine Janssen
PMID 35667914Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.Vaccine2022cited by trial NCT04436276
PMID 35675695Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America2022name in title: Ad26.COV2.S
PMID 35714462Cellular and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients: An observational cohort study.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology2022name in abstract: Ad26.COV2.S
PMID 35727802Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial.PLoS medicine2022cited by trial NCT04838795
PMID 35751559Cutaneous leukocytoclastic vasculitis following COVID-19 vaccination with Ad26.COV2.S vaccine: a case report and literature review.Acta dermatovenerologica Alpina, Pannonica, et Adriatica2022name in title: Ad26.COV2.S
PMID 35798000Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant.Cell reports. Medicine2022cited by trial NCT04889209
PMID 35812459Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients.Frontiers in immunology2022name in title: Ad26COVS1
PMID 35815297Recurrent Myocarditis Following COVID-19 Infection and the mRNA Vaccine.Cureus2022name in abstract: Ad26.COV2.S
PMID 35884709Tolosa-Hunt Syndrome and Hemorrhagic Encephalitis Presenting in a Patient after COVID-19 Vaccination Followed by COVID-19 Infection.Brain sciences2022name in abstract: Ad26.COV2.S
PMID 35911081Severe Thrombocytopenia Two Weeks Following Immunization with the Janssen Ad26.CoV2.S Vaccine.Case reports in hematology2022name in title: Ad26.COV2.S
PMID 36054163Transverse Myelitis Following SARS-CoV-2 Vaccination: A Pharmacoepidemiological Study in the World Health Organization's Database.Annals of neurology2022name in abstract: Ad26.COV2.S
PMID 36113538Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.The Lancet. Infectious diseases2022cited by trial NCT04614948
PMID 36121258Longitudinal Serological Surveillance for COVID-19 Antibodies after Infection and Vaccination.Microbiology spectrum2022name in abstract: Ad26.COV2.S
PMID 36127984Ad26.COV2.S Vaccine-Induced Thrombocytopenia Leading to Dural Sinus Thrombosis and Intracranial Hemorrhage Requiring Hemicraniectomy: A Case Report and Systematic Review.Cureus2022name in title: Ad26.COV2.S
PMID 36146992A probable case of vaccine-induced immune thrombotic thrombocytopenia secondary to Pfizer Comirnaty COVID-19 vaccine.The journal of the Royal College of Physicians of Edinburgh2022name in abstract: Ad26.COV2.S
PMID 36185943Thrombotic Thrombocytopenic Purpura After Ad6.COV2.S Vaccination.Cureus2022name in abstract: Ad26.COV2.S
PMID 36212671Acute-onset chronic inflammatory demyelinating polyneuropathy complicating SARS-CoV-2 infection and Ad26.COV2.S vaccination: report of two cases.The Egyptian journal of neurology, psychiatry and neurosurgery2022name in title: Ad26.COV2.S
PMID 36219526Atypical presentation of Sweet syndrome with nodular erythema and oral ulcerations provoked by Ad26.COV2.S SARS-CoV-2 vaccination and review of literature.Dermatologic therapy2022name in title: Ad26.COV2.S
PMID 36267879Case report: Vaccine-induced immune thrombotic thrombocytopenia complicated by acute cerebral venous thrombosis and hemorrhage after AstraZeneca vaccines followed by Moderna COVID-19 vaccine booster and surgery.Frontiers in neurology2022name in abstract: Ad26.COV2.S
PMID 36274082COVID-19 mRNA Vaccines: A Retrospective Observational Pharmacovigilance Study.Clinical drug investigation2022name in abstract: Jcovden
PMID 36287798Preliminary Analysis of the Effects of Ad26.COV2.S Vaccination on CT Findings and High Intensive Care Admission Rates of COVID-19 Patients.Tomography (Ann Arbor, Mich.)2022name in title: Ad26.COV2.S
PMID 36309347The Incidence and Effect of Adverse Events Due to COVID-19 Vaccines on Breakthrough Infections: Decentralized Observational Study With Underrepresented Groups.JMIR formative research2022cited by trial NCT04832932
PMID 36311588Analyses of reported severe adverse events after immunization with SARS-CoV-2 vaccines in the United States: One year on.Frontiers in public health2022name in abstract: Ad26.COV2.S
PMID 36357712Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial.Nature microbiology2022cited by trial NCT04505722
PMID 36423045Portal Vein and Mesenteric Artery Thrombosis Following the Administration of an Ad26.COV2-S Vaccine-First Case from Romania: A Case Report.Vaccines2022name in title: Ad26.COV2.S
PMID 36655834[Possible vaccine-induced immune thrombotic thrombocytopenia in a patient with diabetes and chronic kidney disease or random association?].Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia2022name in abstract: Ad26.COV2.S
PMID 38620988COVID-19 vaccine (Ad26.COV2.S), an unlikely culprit of portal vein thrombosis in a middle-aged man.Thrombosis update2022name in title: Ad26.COV2.S
PMID 33440088Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.The New England journal of medicine2021cited by trial NCT04436276
PMID 33524316SARS-CoV-2 evolution and vaccines: cause for concern?The Lancet. Respiratory medicine2021cited by trial NCT04505722
PMID 33704352Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.JAMA2021cited by trial NCT04436276
PMID 33852795Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination.The New England journal of medicine2021name in title: Ad26.COV2.S
PMID 33882225Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.The New England journal of medicine2021cited by trial NCT04505722
PMID 33929487US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021.JAMA2021name in title: Ad26.COV2.S
PMID 33980419Thrombotic Thrombocytopenic Purpura after Ad26.COV2-S Vaccination.The American journal of emergency medicine2021name in title: Ad26.COV2.S
PMID 33989437Successful treatment of thrombotic thrombocytopenia with cerebral sinus venous thrombosis following Ad26.COV2.S vaccination.American journal of hematology2021name in title: Ad26.COV2.S
PMID 33997209Widespread annular eruption after Ad26.COV2.S COVID-19 vaccine.JAAD case reports2021name in title: Ad26.COV2.S
PMID 34056055A case of severe cutaneous adverse reaction following administration of the Janssen Ad26.COV2.S COVID-19 vaccine.JAAD case reports2021name in title: Ad26.COV2.S
PMID 34057234Thrombocytopenia and splanchnic thrombosis after Ad26.COV2.S vaccination successfully treated with transjugular intrahepatic portosystemic shunting and thrombectomy.American journal of hematology2021name in title: Ad26.COV2.S
PMID 34096082Vaccine-induced thrombotic thrombocytopenia following Ad26.COV2.S vaccine in a man presenting as acute venous thromboembolism.American journal of hematology2021name in title: Ad26.COV2.S
PMID 34107529Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.Nature2021name in title: Ad26.COV2.S
PMID 34175640Acute Ischemic Stroke Revealing ChAdOx1 nCov-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia: Impact on Recanalization Strategy.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association2021name in abstract: Ad26.COV2.S
PMID 34226070Early Outcomes of Bivalirudin Therapy for Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After Ad26.COV2.S Vaccination.Annals of emergency medicine2021name in title: Ad26.COV2.S
PMID 34337124Cutaneous small vessel vasculitis following single-dose Janssen Ad26.COV2.S vaccination.JAAD case reports2021name in title: Ad26.COV2.S
PMID 34360156COVID-19 Vaccines Safety Tracking (CoVaST): Protocol of a Multi-Center Prospective Cohort Study for Active Surveillance of COVID-19 Vaccines' Side Effects.International journal of environmental research and public health2021cited by trial NCT04834869
PMID 34375510Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites.Journal of thrombosis and haemostasis : JTH2021name in abstract: Ad26.COV2.S
PMID 34408937A COVID-Positive 52-Year-Old Man Presented With Venous Thromboembolism and Disseminated Intravascular Coagulation Following Johnson & Johnson Vaccination: A Case-Study.Cureus2021name in abstract: Ad26.COV2.S
PMID 34447646Facial Diplegia: A Rare, Atypical Variant of Guillain-Barré Syndrome and Ad26.COV2.S Vaccine.Cureus2021name in title: Ad26.COV2.S
PMID 34452028A Case of Acute Pulmonary Embolus after mRNA SARS-CoV-2 Immunization.Vaccines2021name in abstract: Ad26.COV2.S
PMID 34469919Immune-Mediated Thrombocytopenia Associated With Ad26.COV2.S (Janssen; Johnson & Johnson) Vaccine.American journal of therapeutics2021name in title: Ad26.COV2.S
PMID 34477089[Intracerebral haemorrhage twelve days after vaccination with ChAdOx1 nCoV-19].Ugeskrift for laeger2021name in abstract: Ad26.COV2.S
PMID 34496194Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings.The New England journal of medicine2021name in abstract: Ad26.COV2.S
PMID 34516272Transient Thrombocytopenia With Glycoprotein-Specific Platelet Autoantibodies After Ad26.COV2.S Vaccination: A Case Report.Annals of internal medicine2021name in title: Ad26.COV2.S
PMID 34547677Vaccine-Induced Immune Thrombotic Thrombocytopenia with Concurrent Arterial and Venous Thrombi Following Ad26.COV2.S Vaccination.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association2021name in title: Ad26.COV2.S
PMID 34581763Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia.JAMA neurology2021name in abstract: Ad26.COV2.S
PMID 34587255VITT following Ad26.COV2.S vaccination presenting without radiographically demonstrable thrombosis.Blood advances2021name in title: Ad26.COV2.S
PMID 34622311Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study.Rheumatology international2021name in abstract: Ad26.COV2.S
PMID 34659839Deep Venous Thrombosis after Ad26.COV2.S Vaccination in Adult Male.Case reports in critical care2021name in title: Ad26.COV2.S
PMID 34691071Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol.Frontiers in immunology2021name in title: Ad26.COV2.S
PMID 34703690A Rare Variant of Guillain-Barre Syndrome Following Ad26.COV2.S Vaccination.Cureus2021name in title: Ad26.COV2.S
PMID 34790811An unusual presentation of acute deep vein thrombosis after the Moderna COVID-19 vaccine-a case report.Annals of translational medicine2021name in abstract: Ad26.COV2.S
PMID 34824596A plain language summary of how well the single-dose Janssen vaccine works and how safe it is.Future virology2021cited by trial NCT04505722
PMID 34863358Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.Lancet (London, England)2021name in abstract: Ad26.COV2.S
PMID 34887867Inflammation and Platelet Activation After COVID-19 Vaccines - Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and Thrombosis.Frontiers in immunology2021name in abstract: Ad26.COV2.S
PMID 34889361Clots in unusual places: lots of stress, limited data, critical decisions.Hematology. American Society of Hematology. Education Program2021name in abstract: Ad26.COV2.S
PMID 35130405New-onset cutaneous lupus erythematosus after the COVID-19 vaccine.Dermatology online journal2021name in abstract: JNJ-78436735
PMID 33083026Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses.NPJ vaccines2020cited by trial NCT04436276

Other papers

Preclinical studies, reviews and other papers that name it, newest 100 shown.

PubMedTitleJournalYearLinked by
PMID 40180820Effectiveness of BNT162b2 and Ad26.COV2.S vaccines against COVID-19-related hospitalisation amongst adult members of a private health insurance plan in South Africa during the Delta and Omicron periods: A test-negative case-control study.Vaccine2026name in title: Ad26.COV2.S
PMID 40780270Venous Thrombosis Associated with Different Types of SARS-CoV-2 Vaccines in the Netherlands-Results of the TERA Case-Control Study.Thrombosis and haemostasis2026name in abstract: Ad26.COV2.S
PMID 41055073Enhanced adenoviral reactivity in Guillain-Barré syndrome after SARS-CoV-2 infection and vaccination.Brain : a journal of neurology2026name in abstract: Ad26.COV2.S
PMID 41183547Free Nucleic Acids in the ChAdOx1 nCov-19-S Adenovirus Vector Vaccine Contribute to an Anti-platelet Factor 4 Antibody Response.Thrombosis and haemostasis2026name in abstract: Ad26.COV2.S
PMID 41500053COVID-19 vaccination and systemic autoimmune rheumatic diseases: No evidence of disproportionately increased reporting in VAERS.Seminars in arthritis and rheumatism2026name in abstract: Ad26.COV2.S
PMID 41637421A prospective evaluation of Johnson & Johnson COVID-19 vaccine on glycemic biomarkers in type 2 diabetes mellitus in Ethiopia.PloS one2026name in abstract: Ad26.COV2.S
PMID 41708421COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalisations associated with laboratory-confirmed SARS-CoV-2 in Ghana, June 2022 to March 2024.Vaccine2026name in abstract: Jcovden
PMID 41729080Dose-dependent IFN programs in myeloid cells after mRNA and adenovirus COVID-19 vaccination.JCI insight2026name in abstract: Ad26.COV2.S
PMID 41825195A modified self-controlled case series on mortality risk following primary series doses of COVID-19 vaccines in U.S. Medicare beneficiaries aged 65 years and older.Vaccine2026name in abstract: Ad26.COV2.S
PMID 41859091Association of plasma ferritin and plasma iron at time of vaccination with the immune response to SARS-CoV-2 vaccination: a longitudinal cohort study.Frontiers in immunology2026name in abstract: JNJ-78436735
PMID 41901323Incidence of Guillain-Barré Syndrome Following COVID-19 Vaccination and SARS-CoV-2 Infection: A Population-Based Cohort Study Using the Valencia Health System Integrated Database (Spain).Pharmaceuticals (Basel, Switzerland)2026name in abstract: Ad26.COV2.S
PMID 41936925Platelet factor 4 antibody persistence and long-term pathogenicity in vaccine-induced immune thrombotic thrombocytopenia.Journal of thrombosis and haemostasis : JTH2026name in abstract: Ad26.COV2.S
PMID 41953001Antigen-specific IgG glycosylation profiles in hamsters and macaques following COVID-19 vaccination.iScience2026name in abstract: Ad26.COV2.S
PMID 42006303Intranasal replicating adenovirus type 4-vectored SARS-CoV-2 vaccines induce durable and efficacious responses in preclinical testing.iScience2026name in abstract: Ad26.COV2.S
PMID 42051288Intranasal Replicating Adenovirus type 4-SARS-CoV-2 Recombinants Induce Superior Immune Response Durability and Efficacy in Preclinical Testing Compared to Standard Intramuscular Vaccines.bioRxiv : the preprint server for biology2026name in abstract: Ad26.COV2.S
PMID 42094062Humoral Immune Correlates Analysis of Four Vaccines Against SARS-CoV-2 in Rhesus Macaques.Research square2026name in abstract: Ad26.COV2.S
PMID 42128785COVID-19 vaccination and immunoreactant deposition in non-autoimmune oral mucosal pathologies.Oral surgery, oral medicine, oral pathology and oral radiology2026name in abstract: JNJ-78436735
PMID 42168193Long-term cross-variant Fc-mediated immune responses against SARS-CoV-2 induced by a heterologous adenoviral/inactivated virus prime-boost vaccination strategy.NPJ vaccines2026name in abstract: Ad26.COV2.S
PMID 42246858Analysis of adverse events following COVID-19 vaccination and infection: A retrospective, comparative cohort study using a claims database from Discovery Health, a managed care organisation in South Africa.South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde2026name in abstract: Ad26.COV2.S
PMID 42327313Early innate immune signatures correlate with Ad26.COV2.S vaccine durability and protective efficacy.bioRxiv : the preprint server for biology2026name in title: Ad26.COV2.S
PMID 42383724Minor differences in the untranslated regions of measles vector additional transcription units are reflected by differential immunogenicity of encoded MERS-CoV Spike antigen.Journal of virology2026name in abstract: Jcovden
PMID 42403306Potential association of cluster headache with certain COVID-19 vaccines: An assessment from the pharmacovigilance databases.Headache2026name in abstract: Jcovden
PMID 42435835Comparative analysis of non-clinical and clinical safety assessment of COVID 19 vaccines.Regulatory toxicology and pharmacology : RTP2026name in abstract: Ad26.COV2.S
PMID 42468225Using tree-based scan statistics to assess vaccines for possible associations with Guillain-Barré syndrome in the Vaccine Safety Datalink.Vaccine2026name in abstract: Ad26.COV2.S
PMID 42477513Anti-PEG Antibodies From mRNA COVID-19 Vaccines Affect In Vitro Measurements of Pegylated Drug Levels.Clinical and translational science2026name in abstract: Ad26.COV2.S
PMID 42594644Implications for future pandemics from a living systematic review and critical evaluation of observational studies of the effectiveness of COVID-19 vaccination against the Omicron variant.Vaccine2026name in abstract: Ad26.COV2.S
PMID 42929544Early innate immune signatures correlate with Ad26.COV2.S vaccine immunogenicity and protective efficacy.Journal of virology2026name in title: Ad26.COV2.S
PMID 42966246Continued presence and functionality of PF4-antibodies 4.5 years after VITT diagnosis.Blood cells, molecules & diseases2026name in abstract: Ad26.COV2.S
PMID 42973757T-cell recognition of SARS-CoV-2 antigen peptides following booster vaccination with mRNA and viral-vectored COVID-19 vaccines.Frontiers in cellular and infection microbiology2026name in abstract: Ad26.COV2.S
PMID 43005798Long-Term Immunogenicity, Safety, and Reactogenicity of CoronaVac and Heterologous Booster Vaccines: A Two-Year Cohort Study in Brazil.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale2026name in abstract: Ad26.COV2.S
PMID 38030893COVID-19 vaccine-induced immune thrombotic thrombocytopenia: pathophysiology and diagnosis.Annals of hematology2025name in abstract: Ad26.COV2.S
PMID 39327825Modelling antibody dynamics in humans after different Ad26.COV2.S vaccination schemes.British journal of clinical pharmacology2025name in title: Ad26.COV2.S
PMID 39645433Vaccine safety surveillance in South Africa through COVID-19: A journey to systems strengthening.Vaccine2025name in abstract: Ad26.COV2.S
PMID 39739424The association between acute transverse myelitis and COVID-19 vaccination in Korea: Self-controlled case series study.European journal of neurology2025name in abstract: Ad26.COV2.S
PMID 39786643Globally approved vaccines for COVID-19: a systematic review.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2025name in abstract: Ad26.COV2.S
PMID 39843797Empowering African Expertise: Enhancing Safety Data Integration and Signal Detection for COVID-19 Vaccines Through the African Union Smart Safety Surveillance Joint Signal Management Group.Drug safety2025name in abstract: Ad26.COV2.S
PMID 40006661Comparison of Phenotypes of Headaches After COVID-19 Vaccinations Differentiated According to the Vaccine Used.Vaccines2025name in abstract: Jcovden
PMID 40006708Prevalence of Adverse Events Reported Following the First Dose of COVID-19 Vaccines in Bahia State, Brazil, from 2021 to 2022.Vaccines2025name in abstract: Ad26.COV2.S
PMID 40006713Effectiveness of Heterologous and Homologous Ad26.COV2.S Vaccine Boosting in Preventing COVID-19-Related Outcomes Among Individuals with a Completed Primary Vaccination Series in the United States.Vaccines2025name in title: Ad26.COV2.S
PMID 40036106Comparative efficacy of leading COVID-19 vaccines: A network meta-analysis.The Indian journal of medical research2025name in abstract: Jcovden
PMID 40097436Differential efficacy of first licensed western vaccines protecting without immunopathogenesis Wuhan-1-challenged hamsters from severe COVID-19.NPJ vaccines2025name in abstract: Jcovden
PMID 40170841T and B cell responses in different immunization scenarios for COVID-19: a narrative review.Frontiers in immunology2025name in abstract: Ad26.COV2.S
PMID 40196267Prospective SARS-CoV-2 Booster Vaccination in Immunosuppressant-Treated Systemic Autoimmune Disease Patients in a Randomized Controlled Trial.medRxiv : the preprint server for health sciences2025name in abstract: Ad26.COV2.S
PMID 40238055Signal Monitoring for Adverse Events Following Immunisation with COVID-19 Vaccines During the SARS-CoV-2 Pandemic: An Evaluation of the South African Surveillance System.Drug safety2025name in abstract: Ad26.COV2.S
PMID 40289148Disproportionality analysis of European safety reports on autoimmune and rheumatic diseases following COVID-19 vaccination.Scientific reports2025name in abstract: Ad26.COV2.S
PMID 40340265Risk of new-onset seizures following immunization against COVID-19: a self-controlled case-series study.Epidemiology and health2025name in abstract: Ad26.COV2.S
PMID 40348868Comparison of vaccine-induced immune thrombocytopenia and thrombosis cases following two adenovirus-vectored COVID-19 vaccines.Communications medicine2025name in abstract: Ad26.COV2.S
PMID 40388467Longitudinal assessment of COVID-19 vaccine immunogenicity in people with HIV stratified by CD4+ T-cell count in the Netherlands: A two-year follow-up study.PloS one2025name in abstract: Ad26.COV2.S
PMID 40406137Immunological response and implications of Ad26.COV2. S (Janssen COVID-19 vaccine) vaccine in diabetic patients: a prospective cohort study in Ethiopia.Frontiers in immunology2025name in title: Ad26.COV2.S
PMID 40430457Disproportionality Analysis of the Five Most Widespread Neurological Effects of COVID-19 Vaccines from 2021 to 2023: Insights from EudraVigilance.Pharmaceuticals (Basel, Switzerland)2025name in abstract: Jcovden
PMID 40432067COVID-19 Vaccine Perception in Liver Transplant Recipients: Patient-Reported Outcomes and Real-Life Experience from the Bergamo Center.Vaccines2025name in abstract: Jcovden
PMID 40434773Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data: A Secondary Cross-Protocol Analysis of 5 Randomized Clinical Trials.JAMA network open2025name in abstract: Ad26.COV2.S
PMID 40516826Investigating endothelial cell transduction and hexon: platelet factor 4 binding of ChAdOx1 in the context of vaccine-induced thrombotic thrombocytopenia.Journal of thrombosis and haemostasis : JTH2025name in abstract: Jcovden
PMID 40573895Rates of SARS-CoV-2 Breakthrough Infection or Severe COVID-19 and Associated Risk Factors After Primary and Booster Vaccination Against COVID-19 in the Netherlands.Vaccines2025name in abstract: Ad26.COV2.S
PMID 40617090Duration of protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after primary homologous vaccination or first infection.Vaccine2025name in abstract: Jcovden
PMID 40740485SARS-CoV-2 vaccines elicit differential Fc effector functions.iScience2025name in abstract: Ad26.COV2.S
PMID 40872337Anti-SARS-CoV-2 Antibodies in Urine of Individuals Vaccinated with Janssen AD26.COV2.S COVID-19 Vaccine.Pathogens (Basel, Switzerland)2025name in title: Ad26.COV2.S
PMID 40894688Dose-dependent interferon programs in myeloid cells after mRNA and adenovirus COVID-19 vaccination.bioRxiv : the preprint server for biology2025name in abstract: Ad26.COV2.S
PMID 40939515No disproportionate reporting of inflammatory arthritis following COVID-19 vaccination: a pharmacovigilance study using VAERS data.Seminars in arthritis and rheumatism2025name in abstract: Ad26.COV2.S
PMID 41100968Electronic health record analysis reveals no association between COVID-19 vaccines and ischemic stroke.Journal of the neurological sciences2025name in abstract: Ad26.COV2.S
PMID 41195235Perspectives on the impact of regulatory measures on national COVID-19 vaccination programs: a qualitative study from six EU member states.Journal of pharmaceutical policy and practice2025name in abstract: Jcovden
PMID 41210956Immune correlates analysis of antibody responses against SARS-CoV-2 variants in the ENSEMBLE vaccine efficacy trial.iScience2025name in abstract: Ad26.COV2.S
PMID 41258789Strong immunogenicity and protection against SARS-CoV-2 in hamsters induced by heterologous boost vaccination with an MVA-based COVID-19 vaccine candidate.The Journal of general virology2025name in abstract: Ad26.COV2.S
PMID 41310146Immune responses after two inactivated COVID-19 vaccine doses, a heterologous third dose and subsequent boosting with bivalent mRNA in adults.Scientific reports2025name in abstract: Ad26.COV2.S
PMID 41341596Heterologous ORFV-Ad26 vaccination broadens antibody breadth and amplifies cellular immunity against SARS-CoV-2 spike.Frontiers in immunology2025name in abstract: Ad26.COV2.S
PMID 41358289Platelet Factor 4 Antibody Persistence and Long-term Pathogenicity in Vaccine-induced Immune Thrombotic Thrombocytopenia.medRxiv : the preprint server for health sciences2025name in abstract: Ad26.COV2.S
PMID 41378633Real-world effectiveness of Ad26.COV2.S or BNT162b2 booster vaccines against severe COVID-19 in adults who received a primary dose of Ad26.COV2.S in South Africa during the Delta period: A retrospective cohort study using medical scheme data.South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde2025name in title: Ad26.COV2.S
PMID 41403841Safety and immunogenicity of DNA omicron booster Alveavax-v1.2 in Ad26.COV2.S-vaccinated adults.iScience2025name in title: Ad26.COV2.S
PMID 41441716Retrospective Cohort Analysis of Survival After SARS-CoV-2 Infection by Vaccination Status in Jamaica, April-December 2021.Vaccines2025name in abstract: Ad26.COV2.S
PMID 37423396Risk of Herpes Zoster Ophthalmicus After COVID-19 Vaccination in a Large US Health Care Claims Database.American journal of ophthalmology2024name in abstract: Ad26.COV2.S
PMID 37522901Protective effect of vaccination on the risk of cardiovascular disease after SARS-CoV-2 infection.Clinical research in cardiology : official journal of the German Cardiac Society2024name in abstract: Ad26.COV2.S
PMID 38142450Comparison of reporting rates of arthritis and arthralgia following AstraZeneca, Pfizer-BioNTech, Moderna, and Janssen vaccine administration against SARS-CoV-2 in 2021: analysis of European pharmacovigilance large-scale data.Rheumatology international2024name in abstract: Ad26.COV2.S
PMID 38159648Biophysical studies do not reveal direct interactions between human PF4 and Ad26.COV2.S vaccine.Journal of thrombosis and haemostasis : JTH2024name in title: Ad26.COV2.S
PMID 38182460Public's perspective on COVID-19 adenovirus vector vaccines after thrombosis with thrombocytopenia syndrome (TTS) reports and associated regulatory actions - A cross-sectional study in six EU member states.Vaccine2024name in abstract: Jcovden
PMID 38241309Post-marketing active surveillance of Guillain Barré Syndrome following COVID-19 vaccination in persons aged ≥12 years in Italy: A multi-database self-controlled case series study.PloS one2024name in abstract: Ad26.COV2.S
PMID 38255709COVID-19 Crisis in Brazil: Post-Vaccination Seroprevalence and Infection in More and Less Vaccinated Municipalities in a Northeastern State.Life (Basel, Switzerland)2024name in abstract: Ad26.COV2.S
PMID 38293564Determinants of COVID-19 vaccine-induced myocarditis.Therapeutic advances in drug safety2024name in abstract: Ad26.COV2.S
PMID 38343866COVID-19 vaccine uptake and effectiveness by time since vaccination in the Western Cape province, South Africa: An observational cohort study during 2020-2022.medRxiv : the preprint server for health sciences2024name in abstract: Ad26.COV2.S
PMID 38388239Mortality risk after COVID-19 vaccination: A self-controlled case series study.Vaccine2024name in abstract: Ad26.COV2.S
PMID 38388395[Adverse events following immunization reported with COVID-19 vaccines in Burkina Faso: Analysis of spontaneous reports].Sante publique (Vandoeuvre-les-Nancy, France)2024name in abstract: JNJ-78436735
PMID 38398325Vaccine-Induced Immune Thrombotic Thrombocytopenia: Clinicopathologic Features and New Perspectives on Anti-PF4 Antibody-Mediated Disorders.Journal of clinical medicine2024name in abstract: Ad26.COV2.S
PMID 38430718Inverse association with COVID-19 vaccination status of the incidence of pneumonia after SARS-CoV-2 infection: A nationwide retrospective cohort study.Journal of infection and public health2024name in abstract: Ad26.COV2.S
PMID 38486297Risk of encephalitis and meningitis after COVID-19 vaccination in South Korea: a self-controlled case series analysis.BMC medicine2024name in abstract: Ad26.COV2.S
PMID 38563792Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey.Human vaccines & immunotherapeutics2024name in abstract: Ad26.COV2.S
PMID 38603677Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.PLOS global public health2024name in title: Ad26.COV2.S
PMID 38605411How inclusive were UK-based randomised controlled trials of COVID-19 vaccines? A systematic review investigating enrolment of Black adults and adult ethnic minorities.Trials2024name in abstract: Ad26COVS1
PMID 38655202B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S.iScience2024name in title: Ad26.COV2.S
PMID 38655548Landscape review of active vaccine safety surveillance activities for COVID-19 vaccines globally.Vaccine: X2024name in abstract: Ad26.COV2.S
PMID 38662361COVID-19 Vaccine-Associated Uveitis in Patients With a History of Uveitis.JAMA ophthalmology2024name in abstract: Ad26.COV2.S
PMID 38668239Comparative Study of T-Cell Repertoires after COVID-19 Immunization with Homologous or Heterologous Vaccine Booster.Pathogens (Basel, Switzerland)2024name in abstract: Ad26.COV2.S
PMID 38737773Effectiveness of the fourth dose of COVID-19 vaccines against severe COVID-19 among adults 40 years or older in Brazil: a population-based cohort study.Lancet regional health. Americas2024name in abstract: Ad26.COV2.S
PMID 38774878Distinct T cell responsiveness to different COVID-19 vaccines and cross-reactivity to SARS-CoV-2 variants with age and CMV status.Frontiers in immunology2024name in abstract: Ad26.COV2.S
PMID 38779677The single-dose Janssen Ad26.COV2.S COVID-19 vaccine elicited robust and persistent anti-spike IgG antibody responses in a 12-month Ugandan cohort.Frontiers in immunology2024name in title: Ad26.COV2.S
PMID 38793810The Biodistribution of the Spike Protein after Ad26.COV2.S Vaccination Is Unlikely to Play a Role in Vaccine-Induced Immune Thrombotic Thrombocytopenia.Vaccines2024name in title: Ad26.COV2.S
PMID 38804303Antibodies against Platelet Glycoproteins in Clinically Suspected VITT Patients.Antibodies (Basel, Switzerland)2024name in abstract: Ad26.COV2.S
PMID 38823574Establishment of human post-vaccination SARS-CoV-2 standard reference sera.Journal of immunological methods2024name in abstract: Ad26.COV2.S
PMID 38832478Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection by Type and Frequency of Vaccine: A Community-Based Case-Control Study.Journal of Korean medical science2024name in abstract: Ad26.COV2.S
PMID 38839821Identification of cross reactive T cell responses in adenovirus based COVID 19 vaccines.NPJ vaccines2024name in abstract: Ad26.COV2.S
PMID 38846670Genetic Predisposition to Vaccine-Induced Immune Thrombotic Thrombocytopenia: is there a Family Link?European journal of case reports in internal medicine2024name in abstract: Ad26.COV2.S
PMID 38907947What is the Safety of COVID-19 Vaccines in Immunocompromised Patients? Results from the European "Covid Vaccine Monitor" Active Surveillance Study.Drug safety2024name in abstract: Jcovden

NIH grants

ProjectTitleOrganisationPIYearsLinked by
K24AI187743Determinants of Vaccine Responses in Low-Income Countries (LICs)BOSTON UNIVERSITY MEDICAL CAMPUSVALIM, CLARISSA2025–2026name in abstract: Ad26.COV2.S
UM1AI068618CoVPN 3003 A Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older LC 3FRED HUTCHINSON CANCER RESEARCH CENTERMCELRATH, MARGARET JULIANA2020–2022name in title: Ad26.COV2.S
UM1AI068635CoVPN 3003 - A Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older SDMCFRED HUTCHINSON CANCER CENTERGILBERT, PETER B.2021–2022name in title: Ad26.COV2.S
UM1AI148576Vaccine and Treatment Evaluation Units - DMID 21-0012EMORY UNIVERSITYROUPHAEL, NADINE GEORGES2021–2021name in abstract: Ad26.COV2.S

Notes

Replication-incompetent E1-deleted Ad26 encoding a stabilised SARS-CoV-2 spike, made in PER.C6 cells; single intramuscular dose. FDA emergency use authorisation 27 February 2021, revoked June 2023 at the manufacturer's request; EU conditional marketing authorisation 11 March 2021, converted to standard on 9 January 2023 and withdrawn on 26 July 2024 for commercial reasons. UNII taken from the Wikipedia infobox and not from an FDA record.

How to cite

Ad26.COV2.S (AXP000168.2). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000168.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.